Skip to main content

Advertisement

Figure 4 | Molecular Cancer

Figure 4

From: Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Figure 4

Effect of T-DM1 on EGFR-mutant PC9 cell line become resistant to gefitinib for HER-2 overexpression. (A) PC9 and PC9/HER2 c1 cells were exposed to increasing concentrations of T-DM1 for 72 h and then cell viability was assessed by MTT assay. Data are expressed as mean + SD of three different experiments. (B) Immunoblot analysis of proteins of signalling transduction pathways were conducted on cell lysates obtained after treatment with T-DM1 (1 μg/ml) for 24 or 48 h. (C) Curves of growth inhibitory effects of gefitinib and combined treatment gefitinib plus T-DM1 versus theoretical Bliss additivity curve are reported. Cells were treated with the drugs for 72 h and then cell number was assessed by MTT assy. Data are expressed as percent inhibition of cell proliferation versus control cells. The experiments, repeated three times, yielded similar results.

Back to article page